NCT07388615

The Effect of Echinacea (Immulant ®) in the Treatment of CRYPTOSPORIDIOSIS in Immunocompromised Children

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 60 (estimated)
• Sponsor: Al-Azhar University · Academic / Other
• Sex: All
• Age: 5 Years – 12 Years
• Healthy volunteers: Not accepted

Summary

This study aims to: 1. To evaluate the effectiveness of Immulant ® addition to standard treatment in reducing clinical symptoms of Cryptosporidiosis in immunocompromised children. 2. To measure the changes in parasite count in stool samples after treatment with Immulant ®. 3. To assess the safety and tolerability of Immulant ® in children participating in the study.

Detailed description

The present prospective study will be (open labelled) Randomized Clinical Trial and was approved by the Research Ethical Committee Of national nutritional institute. Oral and written consent will be obtained from all patients and controls after a full explanation of the study. A total of at least 60 immunocompromised children consecutively diagnosed with cryptosporidiosis were recruited from the outpatient clinic of National Nutritional Institute.

Conditions

• Cryptosporidium Infection

Interventions

Type	Name	Description
DRUG	Echinacea Extract	Immulant ® (an extract derived from Echinacea purpurea plant)

Timeline

• Start date: 2026-01-18
• Primary completion: 2026-06-01
• Completion: 2026-08-01
• First posted: 2026-02-05
• Last updated: 2026-02-05

Locations

1 site across 1 country: Egypt